PRNewsWire
11 Sept 2026, 08:18 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
2 claims · each scored for market impact
Capricor Therapeutics is facing a class action lawsuit alleging it made false and misleading statements regarding the FDA approval progress of its drug candidate deramiocel. — Securities litigation regarding core product pipeline viability typically triggers investor uncertainty and downward price pressure.
-0.60The lawsuit claims Capricor was aware of adverse data from its Phase 2 HOPE-2 trial while maintaining a positive public narrative. — Allegations of suppressed adverse clinical data directly undermine the fundamental valuation of a biotech company's primary asset.
-0.50Which stocks this story touches
The company is facing a class action lawsuit alleging false and misleading statements regarding its drug candidate and clinical trial data.
Continue reading
5 related stories
Search tags
The company is the subject of a class action lawsuit for securities law violations.
The company is the subject of a class action lawsuit for securities law violations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
12h ago
